Business
PRTC's Vor Announces Collaboration with Janssen
PRTC's Vor Announces Collaboration with Janssen.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6867E\n PureTech Health PLC\n 09 July 2021\n \n \n \n \n 9 July 2021\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)\n \n \n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, \n Vor Biopharma (Nasdaq: VOR) (\"Vor\"), announced the formation of a collaboration with Janssen Biotech, Inc. (\"Janssen\"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.\n \n \n \n \n \n Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vor's \"invisible\" eHSC transplant platform with one of Janssen's bi-specific antibodies in development for acute myeloid leukemia (AML). The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.\n \n \n \n \n \n The full text of the announcement from Vor is as follows:\n \n \n \n \n \n Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)\n \n \n \n \n \n \n CAMBRIDGE, Mass., July 08, 2021\n \n - Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with Janssen Biotech, Inc. (\"Janssen\"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.\n \n \n \n \n \n Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vor's \"invisible\" eHSC transplant platform with one of Janssen's bi-specific antibodies in development for acute myeloid leukemia (AM...